Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Cancers (Basel) ; 16(8)2024 Apr 18.
Article in English | MEDLINE | ID: mdl-38672635

ABSTRACT

BACKGROUND: Minimally invasive surgery in the treatment of colon cancer has significantly advanced over the years. This systematic review and meta-analysis aimed to compare the operative outcomes of robotic and laparoscopic surgery in the treatment of colon cancer, focusing on operative time, hospital stay, conversion rates, anastomotic leak rates, and total number lymph node harvested. METHODS: Following PRISMA guidelines, we conducted a systematic search across four databases up to January 2024, registering our protocol with PROSPERO (CRD42024513326). We included studies comparing robotic and laparoscopic surgeries for colon cancer, assessing operative time, hospital length of stay, and other perioperative outcomes. Risk of bias was evaluated using the JBI Critical Appraisal Checklist. Statistical analysis utilized a mix of fixed and random-effects models based on heterogeneity. RESULTS: A total of 21 studies met the inclusion criteria, encompassing 50,771 patients, with 21.75% undergoing robotic surgery and 78.25% laparoscopic surgery. Robotic surgery was associated with longer operative times (SMD = -1.27, p < 0.00001) but shorter hospital stays (MD = 0.42, p = 0.003) compared to laparoscopic surgery. Conversion rates were significantly higher in laparoscopic procedures (OR = 2.02, p < 0.00001). No significant differences were found in anastomotic leak rates. A higher number of lymph nodes was harvested by robotic approach (MD = -0.65, p = 0.04). Publication bias was addressed through funnel plot analysis and Egger's test, indicating the presence of asymmetry (p = 0.006). CONCLUSIONS: The choice of surgical method should be individualized, considering factors such as surgeon expertise, medical facilities, and patient-specific considerations. Future research should aim to elucidate long-term outcomes to further guide the clinical decision-making.

2.
J Clin Med ; 12(12)2023 Jun 07.
Article in English | MEDLINE | ID: mdl-37373585

ABSTRACT

(1) Background: Patients suffering from chronic wounds report physical, mental, and social consequences due to their existence and care. There is a global need for tissue repair strategies and, in our case, for chronic wound healing. PRP therapy is based on the fact that platelet-derived growth factors (PGF) support the three phases of the wound healing and repair cascade (inflammation, proliferation, and remodeling); (2) Methods: A comparative study was carried out on two groups of patients with atonic wounds totaling a total of 80 cases as follows: a study group in which the PRP procedure was applied and a control group in which the biological product was not injected. The study was carried out in the surgery clinic of the Clinical Hospital C.F. Oradea City; (3) Results: A much faster healing was achieved in the case of patients who benefited from the platelet-rich plasma injection therapy compared to the group of patients in whom this therapy was not used. Three weeks after the plasma injection, a considerable reduction of the wound was evident, with some of the patients presenting with a closed wound; (4) Conclusions: The effect of PRP on the healing of chronic wounds is promising in most cases. A positive effect was also highlighted in terms of reducing treatment costs by considerably reducing the materials used as well as the number of hospitalizations for the same pathology.

3.
Life (Basel) ; 13(6)2023 Jun 03.
Article in English | MEDLINE | ID: mdl-37374101

ABSTRACT

Left ventricular non-compaction (LVNC) is a rare disease defined by morphological criteria, consisting of a two-layered ventricular wall, a thin compacted epicardial layer, and a thick hyper-trabeculated myocardium layer with deep recesses. Controversies still exist regarding whether it is a distinct cardiomyopathy (CM) or a morphological trait of different conditions. This review analyzes data from the literature regarding diagnosis, treatment, and prognosis in LVNC and the current knowledge regarding reverse remodeling in this form of CM. Furthermore, for clear exemplification, we report a case of a 41-year-old male who presented symptoms of heart failure (HF). LVNC CM was suspected at the time of transthoracic echocardiography and was subsequently confirmed upon cardiac magnetic resonance imaging. A favorable remodeling and clinical outcome were registered after including an angiotensin receptor neprilysin inhibitor in the HF treatment. LVNC remains a heterogenous CM, and although a favorable outcome is not commonly encountered, some patients respond well to therapy.

4.
Microorganisms ; 11(6)2023 Jun 15.
Article in English | MEDLINE | ID: mdl-37375087

ABSTRACT

There is growing evidence indicating that the oral microbiota, specifically certain periodontopathogens such as Fusobacterium nucleatum, may play a role in the development of colorectal cancer and that it could potentially be used as a biomarker for diagnosing colorectal cancer (CRC). The question beneath this systematic review is whether the development or progression of colorectal cancer can be attributed to the presence of certain oral bacteria, which could be used for discovering non-invasive biomarkers for CRC. This review aims to give an overview of the actual status of published studies regarding the oral pathogens related to colorectal cancer and assess the effectiveness of the oral microbiome derived biomarkers. A systematic literature search was performed using four databases, Web of Science, Scopus, PubMed, and Science Direct, on the 3rd and 4th of March 2023. The studies that did not have matching inclusion/exclusion criteria were winnowed out. A total of fourteen studies were included. The risk of bias was performed by using QUADAS-2. After assessing the studies, the general conclusion is that oral microbiota-based biomarkers can become a promising non-invasive tool for detecting CRC, but further research is needed in order to determine the mechanisms of oral dysbiosis in colorectal carcinogenesis.

5.
Ann Ital Chir ; 89: 168-176, 2018.
Article in English | MEDLINE | ID: mdl-29848812

ABSTRACT

AIM: Endorectal ultrasonography (ERUS) and high-resolution Magnetic Resonance Imaging (HR-MRI) are two frequently used techniques for the preoperative staging of rectal cancer to offer proper neoadjuvant or surgical treatment. Because tumor restaging after neoadjuvant therapy using ERUS and HR-MRI remains challenging the aim of this study is to determine which of the two imaging methods used in restaging rectal cancer has the highest accuracy. MATERIAL AND METHODS: We included patients with rectal cancer who underwent ERUS and HR-MRI scans before and after neoadjuvant chemo-radiotherapy (n-CRT). The n-CRT was followed by imagistic restaging at 6 weeks after the last therapy session and by surgical resection. The pathology stage from the surgical sample was compared with the HR-MRI and ERUS restaging. RESULTS: Fifty-four patients underwent n-CRT and 47 were restaged by both ERUS and HR-MRI. ERUS was accurate in tumor restaging after n-CRT in 29 cases (61.7%) and HR-MRI in 32 cases (68%). Regarding lymphatic node status, ERUS was accurate for 34 patients (72.3%) and had an overall rate of over-staging of 12.8% and 14.9% of under-staging. HR-MRI was accurate for 30 patients (63.8%) in restaging the lymph nodes after n-CRT and had an overall rate of over-staging of 25.5% and 10.7% of under-staging. CONCLUSION: Restaging rectal cancer after n-CRT remains difficult because of radiotherapy tissue alteration, which results in low diagnostic accuracy for both methods. KEY WORDS: Endorectal Ultrasonography (ERUS), High-Resolution Magnetic Resonance Imaging (HR-MRI), Neoadjuvant Chemo-Radiotherapy, Rectal Cancer Restaging.


Subject(s)
Chemoradiotherapy , Endosonography/methods , Magnetic Resonance Imaging/methods , Neoadjuvant Therapy , Neoplasm Staging/methods , Rectal Neoplasms/pathology , Combined Modality Therapy , Humans , Lymphatic Metastasis , Prospective Studies , Rectal Neoplasms/surgery , Rectal Neoplasms/therapy , Sensitivity and Specificity
6.
Ann Ital Chir ; 882017.
Article in English | MEDLINE | ID: mdl-27941239

ABSTRACT

BACKGROUND AND AIMS: A negative (R0) circumferential resection margin (CRM) is described as one of the most important factor that decrease the rate of local recurrence in rectal cancer. The primary outcome of the study was the status of the CRM, while the secondary outcomes were local recurrence and overall survival. METHODS: Study includes 192 patients with rectal cancer operated between January 2012 and December 2013 in our Institute. The incidence of positive CRM and its impact on the survival rates after oncologic surgical resection were investigated along with factors that determine positive CRM. R1 was defined as a distance of ≤ 1 mm between the tumor and the resection margin. RESULTS: The R1 rate was 3.6 % (7 cases). Nine patients (4.68%) developed local recurrence during a median followup period of 720 days. A positive CRM was found to be a risk factor of local recurrence (p-value = 0.031) and it decreased the overall survival (p-value=0.001). pT4 stage (p-value=0.008) and vascular invasion (p-value=0.005) are factors that play significant roles in determining CRM positivity. In case of inferior rectal tumours abdomino-perineal resection (APR) determines significantly higher (p-value=0.048) rates of positive CRM than anterior resection (AR) of the rectum. CONCLUSIONS: Positive CRM affects overall survival and local recurrence in rectal cancer. pT4 stage and vascular invasion play determinant roles in determine CRM status. APR is a risk factor for positive CRM in inferior rectal tumors. KEY WORDS: Abdomino-perineal resection, Circumferential resection margins, Local recurrence, Rectal cancer, Overall survival.


Subject(s)
Adenocarcinoma/surgery , Colectomy/methods , Margins of Excision , Neoplasm Recurrence, Local/surgery , Rectal Neoplasms/surgery , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Disease-Free Survival , Follow-Up Studies , Humans , Italy/epidemiology , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Rectal Neoplasms/mortality , Rectal Neoplasms/pathology , Retrospective Studies , Risk Factors , Survival Rate , Treatment Outcome
7.
Clujul Med ; 88(3): 348-56, 2015.
Article in English | MEDLINE | ID: mdl-26609269

ABSTRACT

BACKGROUND AND AIMS: The incidence of rectal cancer in the European Union is about 35% of the total colorectal cancer incidence. Staging rectal cancer is important for planning treatment. It is essential for the management of rectal cancer to have adequate preoperative imaging, because accurate staging can influence the therapeutic strategy, type of resection, and candidacy for neoadjuvant therapy. The aim of this work is to evaluate the accuracy of endorectal ultrasound (ERUS) in rectal cancer staging. METHODS: A retrospective study was performed to assess the accuracy of ERUS by analyzing patients discharged from Regional Institute of Gastroenterology and Hepatology (IRGH) Cluj-Napoca, Romania, diagnosed with rectal cancer between 01 January 2011 and 31 December 2013. Patients who were preoperatively staged by other imaging methods and those who had ERUS performed in another service were excluded from the analysis. As inclusion criteria remained ERUS performed for patients with rectal cancer in IRGH Cluj-Napoca where they were also operated. We analyzed preoperative T stage obtained by ERUS and it was compared with the histopathology findings. RESULTS: The number of patients discharged with a diagnosis of rectal cancer were 200 (operated - 157) in 2011, 193 (operated - 151) in 2012, and 198 (operated - 142) in 2013. We analyzed a total of 51 cases diagnosed with rectal cancer who performed ERUS in IRGH Cluj-Napoca. The results according to the T stage obtained by ERUS and histopathology test were: Under-stage T2= 25.0%, T3=7.9% of cases;Over-stage T2=25.0%, T3=31.6% and T4=60.0% of cases.Less than 20% of patients underwent preoperative radio-chemotherapy. CONCLUSIONS: ERUS is a method of staging rectal cancer which is human dependent. ERUS is less accurate for T staging of stenotic tumours, but the accuracy may still be within acceptable limits. Surgeons use ERUS to adopt a treatment protocol, knowing the risk of under-staging and over-staging of this method. The accuracy of ERUS is higher in diagnosing rectal cancer in stages T1, T2 and even in stage T3 with malignant tumor which is not occlusive. ERUS is less accurate for T staging of locally advanced and stenotic tumours.

SELECTION OF CITATIONS
SEARCH DETAIL
...